Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Receivables: 2020-2024

Historic Change in Receivables for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $1.2 million.

  • Xeris Biopharma Holdings' Change in Receivables rose 153.99% to $703,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year increase of 361.25%. This contributed to the annual value of $1.2 million for FY2024, which is 85.44% down from last year.
  • According to the latest figures from FY2024, Xeris Biopharma Holdings' Change in Receivables is $1.2 million, which was down 85.44% from $8.4 million recorded in FY2023.
  • Xeris Biopharma Holdings' Change in Receivables' 5-year high stood at $13.4 million during FY2022, with a 5-year trough of $1.2 million in FY2024.
  • Moreover, its 3-year median value for Change in Receivables was $8.4 million (2023), whereas its average is $7.7 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Change in Receivables soared by 185.84% in 2021, and later crashed by 85.44% in 2024.
  • Yearly analysis of 5 years shows Xeris Biopharma Holdings' Change in Receivables stood at $2.2 million in 2020, then surged by 185.84% to $6.2 million in 2021, then soared by 114.43% to $13.4 million in 2022, then plummeted by 37.44% to $8.4 million in 2023, then slumped by 85.44% to $1.2 million in 2024.